Newsfile Corp
31 Aug 2026, 23:50 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics is facing a class action lawsuit alleging it made misleading statements regarding the regulatory approval prospects of its cell therapy, Deramiocel. — Allegations of misleading investors regarding a core product's approval prospects typically create significant downward pressure on stock price and increase perceived risk.
-0.60The lawsuit claims Capricor changed the statistical analysis plan for Deramiocel clinical data without prior FDA agreement before resubmitting its Biologics License Application (BLA). — FDA disagreement or lack of alignment on data analysis plans significantly increases the risk of a Complete Response Letter (CRL) or regulatory rejection.
-0.50Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to move to serve as lead plaintiff in the litigation. — This is a procedural legal deadline that signals the formal progression of the lawsuit, though it is less material than the underlying regulatory claims.
-0.10Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a securities class action lawsuit alleging materially false and misleading statements regarding FDA clinical data analysis.
The company is mentioned as being subject to a securities class action lawsuit for investors with losses.
The company is mentioned as being subject to a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
